Treatment persistence and medication adherence in patients with schizophrenia treated with brexpiprazole versus other oral atypical antipsychotic therapy -Cohort study using claim database-

Treatment persistence and medication adherence in patients with schizophrenia treated with brexpiprazole versus other oral atypical antipsychotic therapy -Cohort study using claim database- - Treatment persistence and medication adherence in patients with schizophrenia treated with brexpiprazole versus other oral atypical antipsychotic therapy -Cohort study using claim database-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044682

Enrollment

6000

Registered

2021-06-30

Start date

2021-01-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Enrollment period from April 18, 2018 to November 30, 2019 2. Extract patients with schizophrenia who started treatment with BRX during the enrollment period as the BRX group preferentially, then extract patients with schizophrenia who started treatment with atypical antipsychotics other than BRX for schizophrenia during the enrollment period. *Patients who do not prescribe the index drug for any disease for 60 days prior to index date 3. Patients with a diagnosis record for schizophrenia on admission or at two or more outpatient visits in 365-day pre-index date. 4. Patients aged 18 years or older at index date

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with the following diseases in the month of index date or during the 12-month pre-index period. Dementia Attention-Deficit Hyperactivity Disorder (ADHD) Intellectual disability 2. Patients receiving concomitant atypical antipsychotics other than the index drug for more than 30 days after index date 3. Patients who have been prescribed long-acting injectable antipsychotics within 60 days prior to index date 4. Patients who prescribed clozapine in 365-day pre-index date

Design outcomes

Primary

Measure	Time frame
Duration of treatment persistence with the BRX and OAA groups in patients with schizophrenia	—

Secondary

Measure	Time frame
Duration of treatment persistence of the BRX and each drug of OAA* in schizophrenia. Percentage of patients with good adherence to schizophrenia (PDC>=0.8) by BRX, OAA group, and each drug of OAA. Excluding drugs with a small sample size	—

Countries

Japan

Contacts

Public ContactSekine Daisuke

Otsuka Pharmaceutical Co., Ltd. Medical Affairs Department

sekined@otsuka.jp03-6717-1400

Outcome results